Bruker Corporation experienced a sharp 14% drop in stock price after reporting Q2 revenues of $797.4 million, below Wall Street’s expected $810.2 million. The company cited a 7% year-over-year decline in organic revenues, particularly in the US academic, biopharma, and industrial sectors. Despite an 8% increase in life science mass spectrometry revenues, other divisions including BioSpin saw declines. CEO Frank Laukien highlighted challenges from tariffs, currency headwinds, and depressed demand. Rising R&D and SG&A costs added pressure. Bruker lowered its 2025 revenue guidance to a range of $3.43 billion to $3.50 billion, down from prior estimates. This signals ongoing headwinds in key biotech instrumentation markets and cautious outlooks amid economic uncertainties.